It is very uncertain whether oestrogen replacement therapy changes rate of tumour recurrence compared with placebo (very low certainty).
It is very uncertain whether oestrogen replacement therapy changes rate of appearance of a new malignancy compared with placebo (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Chemotherapy with bevacizumab followed by maintenance bevacizumab showed no clear difference in overall survival (OS) compared with chemotherapy alone (moderate certainty).
Chemotherapy with bevacizumab followed by bevacizumab maintenance showed no clear difference in overall survival (OS) compared with chemotherapy alone (moderate certainty).
It is very uncertain whether chemotherapy with bevacizumab followed by maintenance bevacizumab changes progression‐free survival (PFS) compared with chemotherapy alone (very low certainty).
Chemotherapy with bevacizumab followed by bevacizumab maintenance probably leads to lower progression‐free survival (PFS) compared with chemotherapy alone (moderate certainty).
Chemotherapy with bevacizumab followed by bevacizumab maintenance leads to higher any adverse event (grade ≥3) compared with chemotherapy alone (high certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Chemotherapy with bevacizumab followed by maintenance bevacizumab probably leads to higher any adverse event grade ≥ 3 compared with chemotherapy alone (moderate certainty).
Chemotherapy with bevacizumab followed by maintenance bevacizumab may leads to higher hypertension (grade ≥ 2) compared with chemotherapy alone (low certainty).
The review found no eligible studies for this question.
It is very uncertain whether summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy changes any severe adverse event (grade 3 or higher) (G3+ SevAE ) compared with placebo (maintenance therapy) (very low certainty).
The review found no eligible studies for this question.
Summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy showed no clear difference in overall survival (OS) compared with placebo (maintenance therapy) (moderate certainty).
Summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy may leads to lower progression‐free survival (PFS) compared with placebo (maintenance therapy) (low certainty).